← All trials
NCT06612710
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Nov 30, 2025
- Completion date
- Nov 30, 2027
- First posted
- Sep 25, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 69
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyOfficial
- iRegene Therapeutics Co., Ltd.Collaborator
- Huazhong University of Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.